Cargando...
Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future
Glucagon-like peptide-1 (GLP-1)–based therapy improves glycaemic control through multiple mechanisms, with a low risk of hypoglycaemia and the additional benefit of clinically relevant weight loss. Since Starling and Bayliss first proposed the existence of intestinal secretions that stimulate the pa...
Guardado en:
| Publicado en: | Indian J Endocrinol Metab |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4792029/ https://ncbi.nlm.nih.gov/pubmed/27042424 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2230-8210.176351 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|